Change - Announcement of Appointment::APPOINTMENT OF NON-EXECUTIVE CHAIRMAN

Issuer & Securities

Issuer/ Manager
ASIAMEDIC LIMITED
Securities
ASIAMEDIC LIMITED - SG0505000059 - 505
Stapled Security
No

Announcement Details

Announcement Title
Change - Announcement of Appointment
Date &Time of Broadcast
22-Mar-2019 17:44:38
Status
New
Announcement Sub Title
APPOINTMENT OF NON-EXECUTIVE CHAIRMAN
Announcement Reference
SG190322OTHR7BTX
Submitted By (Co./ Ind. Name)
Stanley Woo
Designation
Group Financial Controller
Description (Please provide a detailed description of the event in the box below)
Sponsor statement:
This announcement has been prepared by the Company and reviewed by the Company's sponsor, Xandar Capital Pte Ltd (the "Sponsor"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the correctness of any of the statements made, opinions expressed or reports contained in this announcement.

Contact person for the Sponsor: Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd)
Address: 3 Shenton Way, #24-02 Shenton House, Singapore 068805
Telephone number: (65) 6319 4954


General announcement:
Please also refer to the attached general announcement on composition of the Board of Directors and Board Committees and the appointment of the Acting Chief Operating Officer.

Additional Details

Date Of Appointment
22/03/2019
Name Of Person
Charles Wang Chong Guang
Age
53
Country Of Principal Residence
Hong Kong
The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)
The Nominating Committee has reviewed the credentials and experience of Mr Charles Wang and recommended his
appointment as Non-Executive Chairman of the Company. The Board of Directors has accepted and approved his
appointment based on the recommendation of the Nominating Committee.
Whether appointment is executive, and if so, the area of responsibility
The appointment is non-executive
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Non-Executive Chairman
Professional qualifications
BA (Hons) in Economics and Accounting
Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Mr Wang is currently the Group CEO of Luye Medical Group of which the controlling shareholder, Luye Medical Group Pte Ltd, is part of.
Conflict of interests (including any competing business)
As the CEO of Luye Medical Group, Mr Charles Wang would be overseeing all businesses and operations of the companies in Luye Medical Group. The Company has adopted a shareholders' general mandate for recurrent interested person transactions with certain associates of the Luye Medical Group in 2017. To allay any concerns on future potential conflict of interests which may arise between Luye Medical Group and the AsiaMedic Group, Mr Wang will disclose any potential conflict of interests to the Board and abstain from participating in the Board's deliberations of such matters.
Working experience and occupation(s) during the past 10 years
Feb 2015 - Present
Group CEO, Luye Medical Group

Feb 2015 - Dec 2016
Group Vice President of M&A and Financing, Luye Pharma Group

Jul 2012 - Feb 2015
Chief Financial Officer, China NT Pharma Group

Nov 2010 - Jun 2012
Chief Financial Officer, Trauson Holdings

Dec 2008 - Nov 2010
Chief Financial Officer, Tongjitang Chinese Medicines Company

Jun 1999 - Nov 2008
Chief Financial Officer, Asia Renal Care, Ltd (Asia Pacific HQ)
Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))
No
Shareholding interest in the listed issuer and its subsidiaries?
No
# These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).
Past (for the last 5 years)
Please refer to attachment
Present
Please refer to attachment
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?
No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?
No
(c) Whether there is any unsatisfied judgment against him?
No
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?
No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?
No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?
No
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?
No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?
No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?
No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-
(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or
No
(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or
No
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or
No
(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?
No
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?
No
Any prior experience as a director of an issuer listed on the Exchange?
No
If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange
Mr Wang will attend training on the roles and responsibilities of a director of a listed company

Attachments

Directorships_CW.pdf
Annc_BOD_and_ActCOO_20190322_F.pdf
Total size =28K